Business Context and Reporting Period
Company: Quanterix Corporation (Quanterix)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2017
Business Overview: Quanterix is a life sciences company developing the Simoa (Single Molecule Array) platform, an ultra-sensitive digital immunoassay technology for detecting protein biomarkers in low concentrations. The company targets life science research, diagnostics, and precision health screening markets. Products include the Simoa HD-1 Analyzer (launched 2014) and the Quanterix SR-X (launched December 2017).
Key Event: The company completed its Initial Public Offering (IPO) in December 2017, raising approximately $65.6 million in net proceeds. All outstanding preferred stock converted to common stock upon the IPO.
Key Financial Metrics
| Metric (in thousands) | 2017 | 2016 | 2015 |
|---|---|---|---|
| Total Revenue | $22,874 | $17,585 | $12,180 |
| Net Loss | $(27,019) | $(23,173) | $(15,943) |
| Operating Loss | $(26,005) | $(21,711) | $(14,523) |
| Cash and Cash Equivalents (Year End) | $79,682 | $29,671 | $2,323 |
| Total Long-Term Debt | $9,382 | $10,243 | $9,726 |
| Accumulated Deficit | $(144,352) | $(115,111) | $(88,642) |
Revenue Breakdown (2017): Product revenue was $14.1 million (62%), Service and other revenue was $7.7 million (34%), and Collaboration and license revenue was $1.1 million (5%).
Liquidity: As of December 31, 2017, the company held $79.7 million in cash, bolstered by the IPO. Management believes this is sufficient to fund operations for at least the next 24 months.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 30% year-over-year to $22.9 million, driven by a 33% increase in product revenue (due to more instrument sales and higher consumable usage) and a 53% increase in service revenue (due to higher utilization of the Accelerator Laboratory).
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 58% to $19.7 million, primarily due to headcount additions and stock-based compensation. Research and Development (R&D) expenses decreased slightly by 4% to $16.3 million, as development costs for the SR-X instrument were completed.
- Capital Structure: The company transitioned from a private entity with redeemable convertible preferred stock to a public company with common stock. The IPO resulted in a significant increase in cash and stockholders' equity, turning a deficit of $(115.1) million in 2016 to positive equity of $65.9 million in 2017.
- Debt: The company maintains a secured term loan facility with Hercules Capital, Inc. Total debt remained relatively stable, with principal payments scheduled to begin in earnest in 2018.
Guidance, Outlook, and Risks
Outlook: Management expects to continue incurring significant operating losses for at least the next 24 months as it expands sales, marketing, and R&D efforts. The company plans to leverage the IPO proceeds to fund growth and does not anticipate needing additional funding in the near term, though future capital needs remain uncertain.
Key Risks and Contingencies:
- Profitability: The company has incurred losses since inception and has an accumulated deficit of $144.4 million. There is no guarantee it will achieve or sustain profitability.
- Regulatory Approval: Current products are labeled "Research Use Only" (RUO). Expansion into the diagnostics market requires FDA clearance (510(k)) or approval (PMA), which is expensive, time-consuming, and uncertain.
- Supply Chain: The company relies on single-source contract manufacturers for its instruments (STRATEC for HD-1, Paramit for SR-X) and single-source suppliers for certain consumables (Simoa disks).
- Intellectual Property: Core technology is licensed from Tufts University. Termination of this license would materially harm the business.
- Market Acceptance: Success depends on the adoption of the Simoa platform by researchers and clinicians, which may be slow due to the complexity of the technology and competition.
Investor Verification Checklist
- Cash Runway: Verify the $79.7 million cash balance and the 24-month runway estimate against current burn rates and potential new capital expenditures.
- Debt Covenants: Review the terms of the Hercules Capital loan facility, specifically the negative covenants and the subjective "material adverse effect" clause that could trigger acceleration of debt.
- Minimum Purchase Commitments: Assess the risk associated with the supply agreement with STRATEC, which includes a minimum purchase commitment for HD-1 instruments. Failure to meet this could result in a fee of up to $11.9 million.
- Revenue Concentration: Note that no single customer represented more than 10% of revenue in 2017, but one customer held 16% of accounts receivable.
- Regulatory Pathway: Confirm the status of any ongoing discussions or applications for FDA clearance for diagnostic applications, as this is critical for accessing the larger $30 billion diagnostic market.
- Stock-Based Compensation: Monitor future stock-based compensation expenses, which were $2.2 million in 2017, as the company expands its workforce and equity incentive plans.